XBiotech (STU:4XB) Beginning Cash Position: €100.22 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:4XB XBiotech Inc STU:4XB
38 GF Score
Price €1.86
GF Value €0.15
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is XBiotech Beginning Cash Position?

XBiotech STU:4XB -6.14% 38 Beginning Cash Position is €100.22 Mil as of Jun. 2026. GuruFocus rates STU:4XB with a GF Score™ of 38/100 and a GF Value™ of €0.15 (Significantly Overvalued). The stock has 2 warning signs investors should review.

XBiotech's Beginning Cash Position for the quarter that ended in Jun. 2026 was €100.22 Mil.

XBiotech's quarterly Beginning Cash Position declined from Dec. 2025 (€125.85 Mil) to Mar. 2026 (€108.60 Mil) and declined from Mar. 2026 (€108.60 Mil) to Jun. 2026 (€100.22 Mil).

XBiotech's annual Beginning Cash Position increased from Dec. 2023 (€144.25 Mil) to Dec. 2024 (€191.02 Mil) but then declined from Dec. 2024 (€191.02 Mil) to Dec. 2025 (€147.47 Mil).

XBiotech Beginning Cash Position Related Terms

XBiotech Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for XBiotech's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XBiotech Beginning Cash Position Chart

XBiotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 210.07 223.71 144.25 191.02 147.47

XBiotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 135.16 130.30 125.85 108.60 100.22
STU:4XB
38GF Score
XBiotech Inc STU:4XB
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XBiotech Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €100.22 Mil mean?
XBiotech (STU:4XB) has a Beginning Cash Position of €100.22 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on XBiotech and its competitors.
Is XBiotech's Beginning Cash Position too high?
XBiotech's current Beginning Cash Position is €100.22 Mil. Overall, XBiotech has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XBiotech's Beginning Cash Position compare to LONA and ACRV?
XBiotech's Beginning Cash Position of €100.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on XBiotech and its competitors. XBiotech's current Beginning Cash Position is €100.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XBiotech stock overvalued right now?
Based on GuruFocus' analysis, XBiotech (STU:4XB) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.15, compared to a current price of €1.86 — trading 1142.7% above its estimated fair value. The current Beginning Cash Position is €100.22 Mil. XBiotech's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For XBiotech (STU:4XB), the current Beginning Cash Position is €100.22 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is XBiotech (STU:4XB) Overvalued in 2026?

Based on GuruFocus' analysis, XBiotech stock appears to be overvalued. The current stock price of €1.86 is trading 1142.7% above its estimated GF Value™ of €0.15. GuruFocus considers XBiotech to be Significantly Overvalued.

Key valuation signals for STU:4XB:

  • Beginning Cash Position: €100.22 Mil
  • GF Value™: €0.15 vs. price of €1.86 (1142.7% above fair value)
  • GF Score™: 38/100 with 2 warning signs

No single metric tells the full story. See the STU:4XB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

XBiotech Business Description

Other Exchanges XBIT:USA
Address 5217 Winnebago Lane, Austin, TX, USA, 78744
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
38GF Score

Get the complete analysis for STU:4XB

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.86
Price
€0.15
GF Value